ClinicalTrials.gg
CompletedNCT03487666Updated Dec 3, 2024Results posted

OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease

A Phase 2 interventional study of Nivolumab and Capecitabine in Triple Negative Breast Cancer, sponsored by Georgetown University. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-03.

Sponsored by Georgetown University · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 19 studies testing capecitabine in Triple Negative Breast Neoplasms — 8 open to participants now, 11 under way, 3 of them phase 3. Capecitabine · Triple Negative Breast Neoplasms.

Enrollment
13th of 19
45 · median 154
Started
2018
the only one that year
Phase 2
13 of 19
6 open now
Registered
5th of 19
by date
Lead sponsor
1 of 19
Georgetown University

Among the 19 studies testing capecitabine in Triple Negative Breast Neoplasms, this one is the 13th largest by enrollment, is the only one that started in 2018, is one of 13 in phase 2, and was the 5th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 444 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

8 of the 19 studies testing capecitabine in Triple Negative Breast Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 331 Triple Negative Breast Neoplasms studies recruiting now, 231 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing capecitabine in Triple Negative Breast Neoplasms, or all of them as a file.
02

Study summary

This pilot study will provide preliminary data regarding the role of PIS in predicting the benefit of immune checkpoint inhibition with or without chemotherapy for high risk patients with TNBC and residual disease after effective neoadjuvant chemotherapy.

03

Conditions studied

  • Triple Negative Breast Cancer

Keywords

  • Triple Negative Breast Cancer
  • Nivolumab
  • Capecitabine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. proven TNBC:

    • ER- and PR- defined as ≤5% cells stain positive
    • negativity defined as:

      • IHC 0, 1+ without in situ hybridization (ISH) HER2/neu chromosome 17 ratio OR
      • IHC 2+ and ISH HER2/neu chromosome 17 ratio non-amplified with ratio less than 2.0 and if reported average HER2 copy number \< 6 signals/cells
  2. Residual disease of 1.0 cm at least of the primary tumor and/or node positive disease (at least ypN1)
  3. Patients must have completed chemotherapy; patients must NOT have received capecitabine as part of their neoadjuvant therapy regimen. Acceptable preoperative regimens include an anthracycline or a taxane, or both. Participants who received preoperative therapy as part of a clinical trial may enroll. Participants may not have received adjuvant chemotherapy after s urgery prior to randomization. . Carboplatin-containing neoadjuvant chemotherapy is also allowed). Patients who cannot complete all planned neoadjuvant treatment cycles for any reason are considered high risk and therefore are eligible for the study if they have residual disease.
  4. Recovery of all toxicities from previous therapies to at least grade 1, except alopecia and ≤ grade 2 neuropathy which are allowed.
  5. Must have completed definitive resection of primary tumor and have no evidence of unresected or disease at the time of study entry

    • Negative margins for both invasive and ductal carcinoma in situ (DCIS) are desirable, however patients with positive margins may enroll if the treatment team believes no further surgery is possible and patient has received radiotherapy; patients with margins positive for lobular carcinoma in situ (LCIS) are eligible
    • Either mastectomy or breast conserving surgery (including lumpectomy or partial mastectomy) is acceptable
    • Sentinel node biopsy post neoadjuvant chemotherapy (i.e. at the time of definitive surgery) is allowed; axillary dissection is encouraged in patients with lymph node involvement, but is not mandatory
  6. PS 0-2
  7. Patients must not be planning to receive concomitantly other biologic therapy, hormonal therapy, other chemotherapy, surgery or other anti-cancer therapy except radiation therapy while receiving treatment on this protocol.
  8. At the time of registration (randomization), patients must have the following laboratory results (obtained within 28 days prior to registration):

    1. A serum TSH prior to registration to obtain a baseline value.
    2. Patients must have adequate bone marrow function as evidenced by all of the following:

      • ≥ 1,500 microliter (mcL);
      • ≥ 100,000/mcL;
      • ≥ 9 g/dL.
    3. Patients must have adequate hepatic function as evidenced by the following:

      • Total ≤ 1.5 x institutional (IULN) (except Gilbert's Syndrome, who must have a total bilirubin \< 3.0 mg/dL), and
      • (AST) or SGPT (ALT) and alkaline phosphatase ≤ 2.5 x IULN.
    4. Patients must have adequate renal function as evidenced by ONE of the following:

      • Serum creatinine ≤ IULN OR
      • Measured or calculated ≥ 60 mL/min.
    5. Women of must have a negative urine or serum pregnancy test within 28 days prior to registration and within 24h prior to the start of nivolumab. In addition, women of childbearing potential must agree to have a pregnancy test every 4 weeks while on nivolumab.
  9. Signed ICF
  10. Age ≥18

Exclusion criteria

Exclusion criteria:

  1. Stage IV disease
  2. Receipt of chemotherapy
  3. Diagnosis of other invasive cancer except for adequately treated cervix cancer or skin cancer, or more than 5 years since other diagnosis of invasive cancer without current evidence of disease
  4. Previous exposure to capecitabine, fluorouracil or immunotherapy with anti-PD1, anti-PDL1, anti-CTLA4 or similar drugs.
  5. Active disease that has required systemic treatment in the past 2 years; replacement therapy is not considered a form of systemic therapy
  6. TB, active , active or other active infection. Patients who have completed curative therapy for HCV are eligible. Patients with known infection are eligible if they meet each of the following 3 criteria: ≥ 350 mm3; serum HIV viral load of \< 25,000 IU/ml and treated on a stable antiretroviral regimen.
  7. History of (non-infectious) pneumonitis that required or evidence of active pneumonia
  8. Uncontrolled disease
  9. Chronic use of systemic steroids
  10. within 30 days prior to registration.
  11. Incapacity to provide consent or to follow clinical trial procedures
  12. Pregnancy, lactation, or planning to be pregnant

Patients with microsatellite unstable tumors will not be excluded as immunotherapy as adjuvant therapy is not standard for these patients but we will prospective collect this data.

Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Arm A

    Nivolumab 360 mg iv q3weeks for x 6 cycles

    Drug: Nivolumab

  • Active comparator
    Arm B

    Capecitabine 1250mg/m2 bid D1-D14 q3 weeks x 6 cycles

    Drug: Capecitabine

  • Experimental
    Arm C

    Nivolumab 360mg iv q3weeks + Capecitabine 1250mg/m2 bid D1-D14 q3 weeks x 6 cycles

    Drug: Nivolumab · Drug: Capecitabine

Interventions

  • Nivolumab is a human programmed death receptor-1 (PD-1) antibody currently approved in different diseases.

    Also known as: Opdivo

  • Capecitabine was selected for Arm B given the recent results from CREATE-X trial and the increasing use by the community (feasibility). Importantly, available data from other scenarios indicates that capecitabine does not have immunosuppressive effects

    Also known as: Xeloda

06

What researchers measure

Primary outcomes

  1. Percent Change in the Peripheral Immunoscore (PIS) at Week 6

    PIS were developed using methods previously described (Farsaci, B. et al. Cancer Immunol. Res. 2016), based on tertile distribution of frequencies and ratios of peripheral immune cell subsets in patients prior to therapy. Immune subsets were calculated as a % of PBMC and sorted by frequency. Points were assigned to each subset in a given patient based on tertile distribution. For subsets with an expected positive effect on anti-tumor immunity zero (0) points were assigned to the low bin, one (1) point for the middle bin, and two (2) points if in the high bin. For subsets with an expected negative effect on anti-tumor immunity zero (0) points were assigned to the high bin, one (1) point for the middle bin, and two (2) points if in the low bin. The peripheral immunoscore for a given patient was the sum of points assigned to the individual PBMC subsets that were included within the immunoscore. Positive change means enhanced and negative change means reduced immune function.

    Time frame: 6 weeks

Secondary outcomes

  1. Percent Change of Peripheral Immuno Score (PIS) at Week 12

    PISs were developed using methods previously described (Farsaci, B. et al. Cancer Immunol. Res. 2016), based on tertile distribution of frequencies and ratios of peripheral immune cell subsets in patients prior to therapy. Immune subsets were calculated as a % of PBMC and sorted by frequency. Points were assigned to each subset in a given patient based on tertile distribution. For subsets with an expected positive effect on anti-tumor immunity zero (0) points were assigned to the low bin, one (1) point for the middle bin, and two (2) points if in the high bin. For subsets with an expected negative effect on anti-tumor immunity zero (0) points were assigned to the high bin, one (1) point for the middle bin, and two (2) points if in the low bin. The peripheral immunoscore for a given patient was the sum of points assigned to the individual PBMC subsets that were included within the immunoscore. Positivie change mean enhanced and negative change means reduced immune function.

    Time frame: 12 weeks

  2. Grade 3 and 4 Adverse Events

    The number of grade 3 and 4 adverse events as assessed clinically by an investigator, according to the National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.0 \[NCI CTCAE v4.03\]. Grade 4 adverse events were associated with worse outcomes.

    Time frame: From date of consent until 100 days after the last dose of study treatment, approximately up to 11 months

  3. Invasive Disease Free Survival (DRFS)

    iDFS was defined as the time from date of randomization to the date of first invasive disease recurrence, second invasive primary cancer (breast or not), or death from any cause.

    Time frame: 2 years

  4. Circulating Tumor DNA

    Out of the patients with available ct-DNA samples at baseline, week 6 and week 12, the proportion of patients with detectable ct-DNA at the same timepoints.

    Time frame: 6 weeks and 12 weeks

07

Results

Posted Dec 3, 2024

Participant flow

Participant flow — Overall Study
MilestoneNivolumab (Arm A)Capecitabine (Arm B)Nivolumab + Capecitabine (Arm C)
Started151515
Completed111314
Not completed421
Withdrew: Disease progression420
Withdrew: Adverse event001

Outcome measures

PrimaryPercent Change in the Peripheral Immunoscore (PIS) at Week 6

PIS were developed using methods previously described (Farsaci, B. et al. Cancer Immunol. Res. 2016), based on tertile distribution of frequencies and ratios of peripheral immune cell subsets in patients prior to therapy. Immune subsets were calculated as a % of PBMC and sorted by frequency. Points were assigned to each subset in a given patient based on tertile distribution. For subsets with an expected positive effect on anti-tumor immunity zero (0) points were assigned to the low bin, one (1) point for the middle bin, and two (2) points if in the high bin. For subsets with an expected negative effect on anti-tumor immunity zero (0) points were assigned to the high bin, one (1) point for the middle bin, and two (2) points if in the low bin. The peripheral immunoscore for a given patient was the sum of points assigned to the individual PBMC subsets that were included within the immunoscore. Positive change means enhanced and negative change means reduced immune function.

Time frame:
6 weeks
Reported as:
Mean · % Change in PIS
Percent Change in the Peripheral Immunoscore (PIS) at Week 6
% Change in PISArm A- NivolumabArm B- CapecitabineArm C Nivolumab + Capecitabine
Percent Change in the Peripheral Immunoscore (PIS) at Week 630.63 (-37.5 to 175)-21.9 (-55.56 to 14.286)32.285 (-57.143 to 300)
SecondaryPercent Change of Peripheral Immuno Score (PIS) at Week 12

PISs were developed using methods previously described (Farsaci, B. et al. Cancer Immunol. Res. 2016), based on tertile distribution of frequencies and ratios of peripheral immune cell subsets in patients prior to therapy. Immune subsets were calculated as a % of PBMC and sorted by frequency. Points were assigned to each subset in a given patient based on tertile distribution. For subsets with an expected positive effect on anti-tumor immunity zero (0) points were assigned to the low bin, one (1) point for the middle bin, and two (2) points if in the high bin. For subsets with an expected negative effect on anti-tumor immunity zero (0) points were assigned to the high bin, one (1) point for the middle bin, and two (2) points if in the low bin. The peripheral immunoscore for a given patient was the sum of points assigned to the individual PBMC subsets that were included within the immunoscore. Positivie change mean enhanced and negative change means reduced immune function.

Time frame:
12 weeks
Reported as:
Mean · % Change in PIS
Percent Change of Peripheral Immuno Score (PIS) at Week 12
% Change in PISArm A- NivolumabArm B- CapecitabineArm C Nivolumab + Capecitabine
Percent Change of Peripheral Immuno Score (PIS) at Week 1233.3 (-37.5 to 175)-16.2 (-55.6 to 50)18.83 (-62.5 to 275)
SecondaryGrade 3 and 4 Adverse Events

The number of grade 3 and 4 adverse events as assessed clinically by an investigator, according to the National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.0 \[NCI CTCAE v4.03\]. Grade 4 adverse events were associated with worse outcomes.

Time frame:
From date of consent until 100 days after the last dose of study treatment, approximately up to 11 months
Reported as:
Number · number of adverse events
Grade 3 and 4 Adverse Events
number of adverse eventsArm A- NivolumabArm B- CapecitabineArm C Nivolumab + Capecitabine
Grade 3 Adverse Events283
Grade 4 Adverse Events000
SecondaryInvasive Disease Free Survival (DRFS)

iDFS was defined as the time from date of randomization to the date of first invasive disease recurrence, second invasive primary cancer (breast or not), or death from any cause.

Time frame:
2 years
Reported as:
Median · Months
Invasive Disease Free Survival (DRFS)
MonthsArm A- NivolumabArm B- CapecitabineArm C Nivolumab + Capecitabine
Invasive Disease Free Survival (DRFS)16.75 (3.05 to 41.18)16.04 (0.52 to 37.05)21.37 (7.31 to 35.41)
SecondaryCirculating Tumor DNA

Out of the patients with available ct-DNA samples at baseline, week 6 and week 12, the proportion of patients with detectable ct-DNA at the same timepoints.

Time frame:
6 weeks and 12 weeks
Reported as:
Count of participants · Participants
Circulating Tumor DNA
ParticipantsArm A- NivolumabArm B- CapecitabineArm C Nivolumab + Capecitabine
Baseline644
Week 6621
Week 12631

Adverse events

Collected over Adverse events and serious adverse events collected from date of consent until 100 days after the last dose of study treatment, approximately up to 11 months. All cause mortality collected for up to 3 years after study drug discontinuation.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A- Nivolumab5/15 (33.3%)3/15 (20%)14/15 (93.3%)
Arm B- Capecitabine2/15 (13.3%)0/15 (0%)15/15 (100%)
Arm C Nivolumab + Capecitabine2/15 (13.3%)3/15 (20%)15/15 (100%)
Most frequent serious events
Most frequent serious events
EventArm A- NivolumabArm B- CapecitabineArm C Nivolumab + Capecitabine
Abdominal PainGastrointestinal disorders1/150/151/15
Breast infectionInfections and infestations0/150/151/15
DiarrheaGastrointestinal disorders0/150/151/15
Surgical and medical procedures - Other, specifySurgical and medical procedures1/150/150/15
PneumonitisRespiratory, thoracic and mediastinal disorders1/150/150/15
Most frequent other events
Showing 10 of 97
Most frequent other events
EventArm A- NivolumabArm B- CapecitabineArm C Nivolumab + Capecitabine
Palmar-plantar erythrodysesthesia syndromeSkin and subcutaneous tissue disorders0/157/1511/15
DiarrheaGastrointestinal disorders3/158/157/15
FatigueGeneral disorders7/155/157/15
NauseaGastrointestinal disorders0/155/153/15
ArthralgiaMusculoskeletal and connective tissue disorders5/151/151/15
HypothyroidismEndocrine disorders3/150/154/15
Peripheral sensory neuropathyNervous system disorders1/154/154/15
Rash maculo-papularSkin and subcutaneous tissue disorders4/151/150/15
ConstipationGastrointestinal disorders1/150/153/15
Mucositis oralGastrointestinal disorders0/153/153/15

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Arm A- NivolumabArm B- CapecitabineArm C Nivolumab + CapecitabineTotal
<=18 years0000
Between 18 and 65 years14141341
>=65 years1124
Sex: Female, Male
Sex: Female, Male(Participants)Arm A- NivolumabArm B- CapecitabineArm C Nivolumab + CapecitabineTotal
Female15151545
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A- NivolumabArm B- CapecitabineArm C Nivolumab + CapecitabineTotal
Hispanic or Latino1124
Not Hispanic or Latino14131340
Unknown or Not Reported0101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A- NivolumabArm B- CapecitabineArm C Nivolumab + CapecitabineTotal
American Indian or Alaska Native0000
Asian1001
Native Hawaiian or Other Pacific Islander0101
Black or African American26715
White116825
More than one race0000
Unknown or Not Reported1203
08

Study locations

4 sites
  • MedStar Georgetown University Hospital
    Washington, District of Columbia 20007, United States
  • MedStar Washington Hospital Center
    Washington, District of Columbia 20010, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • John Theurer Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Nov 2021, 41 months.

Results were first posted in Dec 2024, 3 years 1 month after primary completion.

Of 220 non-industry phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 99. This study's 41 months is below that.

Counting every sponsor, half of 255 studies reached it within 59 months; a quarter within 37 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2018
First posted
Apr 4, 2018
StartActual
May 21, 2018
Primary completionActual
Nov 3, 2021
CompletionActual
May 2, 2024
Results first posted
Dec 3, 2024
Last update
Dec 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03487666
Responsible party
Sponsor
First posted
Apr 4, 2018
Start date
May 21, 2018
Primary completion
Nov 3, 2021
Completion
May 2, 2024
Results posted
Dec 3, 2024
Last update
Dec 3, 2024

Study contacts

Candace Mainor, MD
study chair · MedStar Georgetown University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Capecitabine

Start the discussion